
doi: 10.1111/febs.13668
pmid: 26807978
Malignant cells may subvert and escape endogenous host immune surveillance by up‐regulation of immune inhibitory signals known as immune checkpoints. These checkpoints are important therapeutic targets, and antibodies that block checkpoint signaling have shown remarkable efficacy in some solid tumors as well as in some refractory hematologic malignancies. In hematologic cancers, the mechanism of these checkpoints is complex, as the tumor and immune system are one and the same. In this review, we evaluate the biology of checkpoint inhibition, review the current data on its efficacy in lymphoid tumors, and explore uncertainties in the field, including those involving the precise mechanisms of action, the appropriate timing of therapy, and the differences in response rate between lymphoid tumor types.
Lymphoma, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Cell Cycle Checkpoints, CD8-Positive T-Lymphocytes, B7-H1 Antigen, Hematologic Neoplasms, Humans, CTLA-4 Antigen, Immunotherapy, Molecular Targeted Therapy
Lymphoma, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Cell Cycle Checkpoints, CD8-Positive T-Lymphocytes, B7-H1 Antigen, Hematologic Neoplasms, Humans, CTLA-4 Antigen, Immunotherapy, Molecular Targeted Therapy
| citations The total number of citations received by all articles of the researcher of interest. | 24 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 10% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
